Investor updates Suchbegriff Suchen Löschen 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 Published on: 17 Januar 2019 FDA accepts Roche’s supplemental biologics license application for Tecentriq plus chemotherapy (Abraxane and carboplatin) for the initial treatment of metastatic non-squamous non-small cell lung cancer Roche today announced that the US Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Application (sBLA) for Tecentriq® (atezolizumab) in combination with ... mehr Published on: 7 Januar 2019 Invitation to Roche's Full Year Results 2018 Presentation Roche will publish its Full Year Results for 2018 prior to the opening of the Swiss Stock Exchange on Thursday, 31 January 2019. mehr
Published on: 17 Januar 2019 FDA accepts Roche’s supplemental biologics license application for Tecentriq plus chemotherapy (Abraxane and carboplatin) for the initial treatment of metastatic non-squamous non-small cell lung cancer Roche today announced that the US Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Application (sBLA) for Tecentriq® (atezolizumab) in combination with ... mehr
Published on: 7 Januar 2019 Invitation to Roche's Full Year Results 2018 Presentation Roche will publish its Full Year Results for 2018 prior to the opening of the Swiss Stock Exchange on Thursday, 31 January 2019. mehr